OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bekaii-Saab on Moving Metastatic Treatment Strategies to the Adjuvant Setting in CRC

May 2nd 2020

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses moving metastatic treatment strategies to the adjuvant setting in colorectal cancer (CRC).

Dr. Awan on Remaining Questions With BTK Inhibitors and Anti-CD20 Combos in CLL

May 2nd 2020

Farrukh Awan, MD, discusses remaining questions regarding the use of BTK inhibitors and CD20-directed monoclonal antibodies in chronic lymphocytic leukemia.

Dr. Hidalgo Medina on the Rationale for Using Patient-Derived Organoids in Pancreatic Cancer

May 2nd 2020

Manuel Hidalgo Medina, MD, PhD, chief, Division of Hematology and Medical Oncology, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses that rationale for using patient-derived organoids (PDOs) in pancreatic cancer.

Dr. Wright on Proton Versus Photon Radiotherapy in Breast Cancer

May 2nd 2020

Jean Wright, MD, discusses proton versus photon radiotherapy in breast cancer.

Dr. Powles on the 42-Month Follow-Up Data From the CheckMate-214 Trial in RCC

May 2nd 2020

Thomas Powles, MD, MBBS, MRCP, director, Barts Cancer Institute, discusses the 42-month follow-up data from the phase 3 CheckMate-214 trial in advanced renal cell carcinoma (RCC).

Dr. Stone on Combinations With Venetoclax in AML

May 2nd 2020

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses combinations with venetoclax (Venclexta) in acute myeloid leukemia (AML).

Dr. Naumann on Data With STRO-002 in Platinum-Resistant/Refractory Ovarian Cancer

May 2nd 2020

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses data with STRO-002 in patients with platinum-resistant/refractory ovarian cancer.

Advantages of Off-the-Shelf CAR NK Therapy in B-Cell Malignancies

May 1st 2020

Bob Valamehr, PhD, chief development officer at Fate Therapeutics, discusses the advantages of off-the-shelf CAR NK therapy in B-cell malignancies.

Dr. Petrylak on the Results of the EV-103 Trial in Bladder Cancer

May 1st 2020

Daniel P. Petrylak, MD, professor of medicine and urology, co-leader, Cancer Signaling Networks, Yale Cancer Center, and 2017 Giant of Cancer Care® in Genitourinary Cancers, discusses the results of the phase 1b/2 EV-103 trial in bladder cancer.

Dr. Pavlick on the COLUMBUS Trial in Metastatic Melanoma

May 1st 2020

Anna C. Pavlick, DO, discusses updated results from the COLUMBUS trial in metastatic melanoma.

Dr. Trent on Research Efforts in Bone and Soft Tissue Sarcomas

May 1st 2020

Jonathan C. Trent, MD, PhD, discusses research efforts in bone and soft tissue sarcomas.

Dr. Chen on Rapid Research Autopsy in Rare Cancer

May 1st 2020

Hui-Zi Chen, MD, PhD, discusses the use of rapid research autopsy in metastatic ultra-hypermutated interdigitating dendritic cell sarcoma, an extremely rare cancer of dendritic origin that lacks a standardized treatment approach.

Dr. O'Regan on Breast Cancer Treatment Considerations During the COVID-19 Crisis

May 1st 2020

Ruth O’Regan, MD, provides insight on how the COVID-19 crisis is impacting the care of patients with breast cancer.

Alternate Delivery Models for Genetic Counseling in Prostate Cancer

April 30th 2020

Alanna K. Rahm, PhD, MS, discusses alternate delivery models for genetic counseling in prostate cancer.

Dr. Graff on Combination Regimens With Checkpoint Inhibitors in mCRPC

April 30th 2020

Julie N. Graff, MD, discusses potential combination regimens with checkpoint inhibitors in metastatic castration-resistant prostate cancer.

Dr. Oh on Adapting the PRINT Trial Model to Other Settings in Prostate Cancer

April 30th 2020

William K. Oh, MD, discusses adapting the phase 2 PRINT trial model to other settings in prostate cancer

Dr. Hamid on Potential Combinations With Docetaxel in mHSPC Subtypes

April 30th 2020

Anis Hamid, MBBS, discusses potential combination with docetaxel in metastatic hormone-sensitive prostate cancer subtypes.

Dr. Cuellar on the Pharmacoeconomic Benefits of Biosimilars

April 30th 2020

Sandra Cuellar, PharmD, BCOP, discusses the pharmacoeconomic benefits of biosimilars.

Dr. Abraham on Potential Symptoms of TGCT

April 30th 2020

John A. Abraham, MD, FACS, discusses potential symptoms of tenosynovial giant cell tumor.

Dr. Ferris on Ongoing Research With STING Agonists/Checkpoint Inhibitors in Head and Neck Cancer

April 30th 2020

Robert L. Ferris, MD, PhD, discusses ongoing research with STING agonists and checkpoint inhibitors in head and neck cancer.